HCW BIOLOGICS INC (HCWB)
US40423R1059 - Common Stock
Thursday's session: top gainers and losers
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
These stocks are moving in today's after hours session
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
In today's session, these stocks are experiencing unusual volume.
Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Top movers in Tuesday's pre-market session
Pre-market stock analysis on 2024-11-19: top gainers and losers in today's session.
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules...
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
HCW Biologics signed license agreement with WY Biotech...
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
Press release for Q3 2024 business highlights and financial results...
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
Results of Q2 2024, including settlement of long-running arbitration. ...
HCWB Stock Earnings: HCW Biologics Reported Results for Q2 2024
HCW Biologics just reported results for the second quarter of 2024.
HCWB Stock Earnings: HCW Biologics Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips HCW Biologics (NASDAQ:HCWB) just reported results for the second quarter of 202...
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
Results of Q2 2024, including settlement of long-running arbitration. ...
HCWB Stock Earnings: HCW Biologics Reported Results for Q1 2024
HCW Biologics just reported results for the first quarter of 2024.
HCWB Stock Earnings: HCW Biologics Reported Results for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips HCW Biologics (NASDAQ:HCWB) just reported results for the first quarter of 2024...
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
Earning release for Q1 2024...
HCWB Stock Earnings: HCW Biologics Misses EPS, Misses Revenue for Q4 2023
HCWB stock results show that HCW Biologics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
HCWB Stock Earnings: HCW Biologics Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips HCW Biologics (NASDAQ:HCWB) just reported results for the fourth quarter of 202...
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
Q4 and Year End Earnings Release and Business Highlights...
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights ...
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors. ...
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
HCW9218 is the lead product candidate of HCW Biologics Inc.
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
Masonic Cancer Center, University of Minnesota to Present Human Data Readout for HCW9218 Phase 1 Study at SITC 2023...
HCW Biologics director Gary Winer buys shares worth $3.3k - filing (NASDAQ:HCWB)
HCW Biologics (HCWB) director Gary Winer disclosed in an SEC filing on Friday after the bell a purchase of 1,587 shares of the company at prices ranging from $2, $2.05, and $2.08 per...
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the...
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical...